Business Context and Reporting Period
Immunic, Inc. (IMUX), a Delaware corporation, filed this Form 8-K on December 29, 2020. The company is engaged in the clinical development of product candidates and is listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing is a Current Report regarding a material definitive agreement and does not contain audited financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for these financial indicators.
Material Changes
On December 29, 2020, Immunic entered into a new Sales Agreement with SVB Leerink LLC. Key terms include:
- Offering Capacity: The company may offer and sell common stock with an aggregate offering price of up to $50,000,000.
- Method: Sales will be conducted as an "at the market" offering through SVB Leerink acting as agent.
- Commission: SVB Leerink will receive a commission of 3.0% of the gross proceeds from sales.
- Existing Agreement: A prior Sales Agreement dated July 17, 2019, allowing for up to $40,000,000 in sales, remains in effect.
Guidance, Outlook, and Management Commentary
Use of Proceeds: The company intends to use net proceeds from the offering to fund ongoing clinical development of product candidates, fund existing and potential new clinical programs, and for general corporate purposes.
Termination: The agreement may be terminated by either party upon ten days' prior notice, or by SVB Leerink in certain circumstances, including a material adverse effect on the company.
Risks and Contingencies: The company is not obligated to sell any shares. The agreement is subject to customary terms and conditions, including applicable laws and Nasdaq rules.
Investor Verification Checklist
- Verify the total amount of shares sold under both the new ($50M) and prior ($40M) Sales Agreements to date.
- Review the company's most recent 10-K or 10-Q for actual cash position and burn rate to assess the necessity of this capital raise.
- Confirm the current status and milestones of the clinical programs mentioned as the intended use of proceeds.
- Monitor the 3.0% commission impact on net proceeds relative to the gross offering price.